On January 20, 2022 Yingli Pharma US, Inc. (the "Company" or "Yingli"), a biotechnology company developing innovative small molecules, and The University of Texas MD Anderson Cancer Center reported a strategic alliance to advance several oncology programs from preclinical discovery through clinical development (Press release, Yingli Pharmaceutical, JAN 20, 2022, View Source [SID1234606682]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The five-year collaboration brings together Yingli’s experience in medicinal chemistry with MD Anderson’s comprehensive clinical and translational resources to drive existing Yingli therapeutic candidates into four U.S.-based clinical trials and to facilitate preclinical discovery and development in additional indications.
"This tremendous opportunity will accelerate our efforts as we look to bring new pharmacological agents to cancer patients in need," said Michael Hui, MBA, chief executive officer of Yingli. "We look forward to working with the experts at MD Anderson, complementing our own expertise as we continue to build a well-rounded oncology pipeline."
Two of the programs supported by the collaboration will leverage favorable clinical trial findings collected from China-based studies. The first program will focus on linperlisib, a PI3Kδ inhibitor with a novel structure, which has had positive results in eight active or completed Phase 1 and Phase 2 clinical trials for patients with lymphomas and solid tumors, including peripheral T cell lymphoma (PTCL).
"We are pleased to be working with Yingli to initiate a Phase 2 clinical trial evaluating linperlisib in patients with PTCL," said principal investigator Swaminathan Iyer, M.D., professor of Lymphoma & Myeloma at MD Anderson. "This collaboration brings a potentially effective treatment option with a favorable safety profile to the U.S. to address an unmet need for patients with this aggressive cancer. I look forward to leading this exciting study."
The second program will develop YL-13027, a novel, oral TGFβR1 inhibitor for use in advanced solid tumors with plans to initiate a U.S.-based Phase 1 clinical trial in 2022, led by Jordi Rodon, M.D., Ph.D., associate professor of Investigational Cancer Therapeutics at MD Anderson.
"The TGFβ pathway is an important immune regulator in the tumor microenvironment, and new treatments focused on enhancing anti-tumor immunity are desperately needed," Rodon said. "We look forward to working with Yingli to conduct the first U.S.-based clinical trial evaluating their TGFβR1 inhibitor."
In addition to advancing existing clinical programs, the collaboration also will focus on translational studies to further Yingli’s discovery programs. The collaborative approach will provide a steady stream of new therapeutic candidates for oncology clinical development, which the MD Anderson team, including David S. Hong, M.D., deputy chair of Investigational Cancer Therapeutics, will investigate.
About Linperlisib
Linperlisib (YY-20394) is a highly selective and potent PI3Kδ inhibitor that has shown a favorable safety profile, encouraging anti-tumor activities and promising PK and pharmaceutical properties as an oral once-a-day agent in late-stage clinical development. A Phase 1 clinical trial was completed in 2020 demonstrating linperlisib to be a safe and tolerable agent, and a recommended Phase 2 dose of 80 mg QD was established. Linperlisib was awarded NMPA Breakthrough Therapy status in China, leading to a Phase 2 study in follicular lymphoma (FL) that was completed and submitted in 2021 to China marketing authority for approval. In addition, linperlisib received FDA Orphan Drug Designations for FL, CLL/SLL and T cell lymphoma. Multiple linperlisib clinical trials being conducted in FL, PTCL, other lymphomas, solid tumors, combination with gemcitabine/oxaliplatin in r/r DLBC and combination with therapeutic PD1 antibody are underway in China and the U.S. Preliminary results of single agent linperlisib from a relapsed or recurrent PTCL Phase1b study were reported at ASCO (Free ASCO Whitepaper) 2021, indicating an overall response rate of 70% with 33% CRs for this difficult to treat and aggressive form of lymphoma.
About YL-13027
YL-13027 is a potent small molecule antagonist of TGFβR1 kinase in early-stage clinical development. The compound was optimized with selectivity against TGFβR2 and other kinases, differentiating YL-13027 from other inhibitors blocking TGFβ signaling. In preclinical studies, YL-13027 demonstrated anti-tumor efficacy, tumor immune modulation and combination benefit with immunotherapy. In IND-enabling studies, YL-13027 showed reliable dose-proportionality and pharmacokinetic properties, and the agent proved to be safe and tolerable in toxicity studies. The preliminary results of a Phase 1 dose escalation clinical trial of single agent YL-13027 were reported at ASCO (Free ASCO Whitepaper) 2021, including the safety and efficacy findings that the open-label study is continuing in order to establish a recommended Phase 2 dose of YL-13027.